TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04094246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-surgical rehabilitation
Description: Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
Study: NCT02805608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NOTA-AE105
Description: One injection intravenously of 68Ga-NOTA-AE105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 18F-FDG
Description: One injection intravenously of 18F-FDG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and CT
Description: Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and MRI
Description: Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
Study: NCT03358966

Intervention type: OTHER
Intervention: Doubly-labelled water technique

Intervention type: OTHER
Intervention: Doubly-labelled water technique

Intervention type: OTHER
Intervention: Resting Energy Expenditure
Description: Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.

Intervention type: OTHER
Intervention: Resting Energy Expenditure
Description: Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
Study: NCT01779687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Raltegravir 400 mg BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: Raltegravir 400 mg BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg QD for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg QD for 7 days
Study: NCT04181151

Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.

Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
Study: NCT00701077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Di-amino-Pyridine
Description: a single 20 mg dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03519165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EV1000(FloTrac System 4.0)
Study: NCT01519466

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle InsuLinx
Description: FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Freedom Lite
Description: FreeStyle Freedom Lite is a blood glucose meter
Study: NCT04744285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette packaging
Description: receive normal packet cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette packaging
Description: receive normal packet cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette packaging
Description: receive normal packet cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette packaging
Description: receive normal packet cigarette

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data capture
Description: Attend video sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data capture
Description: Attend video sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data capture
Description: Attend video sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data capture
Description: Attend video sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT02688959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT00926211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTAS™ System
Description: Hair harvest using a computer-assisted system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Hair Harvest
Description: Hair harvesting via the manual technique
Study: NCT01074619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Study: NCT01578759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Removal of the fallopian tubes
Study: NCT06649578

Intervention type: PROCEDURE
Intervention: Metabolic-bariatric surgery
Description: Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
Study: NCT04664673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)
Description: motor learning-based, intensive therapy originally developed for hemiplegic children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: customary or usual treatment given to any adult stroke survivor
Study: NCT02426879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagectomy with three-field lymphnode dissection
Description: robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
Study: NCT04746443

Intervention type: OTHER
Intervention: NOT APPLICABLE (NA)
Description: THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
Study: NCT00939679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Description: Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass surgery
Description: Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low calorie diet (1,000 kcal/day)
Description: Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet (1,000 kcal/day)
Description: Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period.
Study: NCT03000361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motorized Spiral Colonoscopy
Description: For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
Study: NCT02072447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 PO and [14C]-YH4808 IV
Study: NCT03797079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter insertion
Description: After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter insertion
Description: After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
Study: NCT02594124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study: NCT03555474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Patients received active and passive physiotherapy of the affected extremity for four weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients received active and passive physiotherapy of the affected extremity for four weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Patients received active and passive physiotherapy of the affected extremity for four weeks.
Study: NCT00434473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-001
Description: A-001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03731507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of Range of Motion with Kinect Controller
Description: A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
Study: NCT00815672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive walking and resistance exercise treatment
Study: NCT00504881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
Study: NCT03498482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
Description: FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
Study: NCT04372407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib: 200 mg as single dose on Days 1 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
Study: NCT02912325

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Daily administration: 2 tablets FaseMETS a day
Description: Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
Study: NCT02148614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Libramed
Description: Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
Study: NCT05146687

Intervention type: OTHER
Intervention: Aflibercept
Description: intravitreal injection

Intervention type: OTHER
Intervention: Ranibizumab
Description: intravitreal injection

Intervention type: OTHER
Intervention: Bevacizumab
Description: intravitreal injection
Study: NCT03252171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
Study: NCT04499274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 ul of ondansetron
Description: Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2 ul of ondansetron
Description: Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ul of ondansetron
Description: Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 ul of ondansetron
Description: Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
Study: NCT02100397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella enterica serovar Paratyphi A (strain NVGH308)
Description: Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
Study: NCT02127918

Intervention type: DRUG
Intervention: ESES treated with clobazam
Description: The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
Study: NCT01115790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
Study: NCT01492530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men of African American Legacy Empowering Self
Description: Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HIV Education & Risk Reduction
Description: Single, individual counseling and education session. Lasting 20-30 minutes.
Study: NCT02730364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C
Description: One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
Study: NCT04144504

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retrievable metallic stenting
Description: Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stenting
Description: Use of plastic stents
Study: NCT04427501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered IV
Study: NCT03123731

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Wearing Physical Activity Monitor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTEP
Description: Physical Activity Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSTEP
Description: Physical Activity and Diet Intervention
Study: NCT06602947

Intervention type: OTHER
Intervention: Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation
Description: 1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance.

Intervention type: OTHER
Intervention: Low flow anaesthesia using ASA enviormental sustanibility commitee recomendation
Description: 1. Induction: Set the Vaporizer to Deliver a Concentration Greater than Intended~2. Intubation: Turn Off the Fresh Gas Flow, Not the Vaporizer.~3. Maintanance: Minimize Fresh Gas Flow During Maintenance.
Study: NCT04427501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3853113
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT04083612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
Study: NCT02751567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study: NCT03371030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronatus quadratus reparation
Description: Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pronatus quadratus reparation
Description: Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
Study: NCT01258335

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)